# Phase 1 completion report

## Scope and sources

Phase 1 delivered the frontend foundation and accessible marketing shell described in PRD §§3.1, 5, 8, 9.1–9.10, 11.1–11.6, 12.1–12.3, 21, 26.1/26.3, and 28 Phase 1.

Figma sources: palette `6026:3`; DP Option 2 + App Icon `6021:115`, including R/pill artwork `6021:128`. The official R/pill asset is stored as `frontend/public/brand/r-pill-mark.svg`; provenance is recorded in `docs/brand-export-manifest.md`.

## Files and implementation

- `frontend/app/*`, `frontend/components/*`, and configuration establish the Next.js/TypeScript/Tailwind marketing shell.
- `frontend/public/brand/r-pill-mark.svg` and `frontend/public/product-preview/app-icon.png` are direct Figma assets.
- `frontend/tests/*` contains one unit test and responsive browser verification.
- `docs/evidence/phase-1/marketing-{320,390,768,1024,1440}.png` contains sanitized visual evidence.

## Verification

Passed commands: `npm run format:check`, `npm run lint`, `npm run typecheck`, `npm test -- --reporter=verbose`, `npm run build`, and `npm run test:e2e`.

Playwright verified no body horizontal overflow, logo visibility, preview content, keyboard focus to the home link, and reduced-motion rendering at 320, 390, 768, 1024, and 1440px.

Chrome DevTools verified no error/warn console messages on a fresh load. Required HTML, font, SVG logo, app-icon, CSS, and JavaScript requests returned 200 or 304; the prior 400 logo request and missing favicon request were fixed by correcting the direct Figma SVG filename and declaring the metadata icon.

## Accessibility and limitations

The page uses semantic landmarks, heading levels, accessible link labels, visible focus styling, 44px CTA minimums, reduced-motion CSS, descriptive app-icon alt text, and decorative empty alt text for the mark. It intentionally has no waitlist form, API, health-data input, medical advice, or prescription processing.

## Final verdict

PHASE 1 VERIFIED COMPLETE
